Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIASTAT ACUDIAL vs AZMIRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to GABA-A receptors, enhancing GABA effects and increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of seizure activity.
Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.
Status epilepticus,Acute repetitive seizures,Adjunctive treatment for epilepsy
Treatment of Ductal Carcinoma In Situ (DCIS) following breast surgery and radiation,Breast cancer risk reduction in premenopausal women at high risk,Off-label: Anovulatory infertility, Osteoporosis prevention in postmenopausal women
2.5 mg to 20 mg rectally, as a single dose for acute seizure clusters; may repeat once after 4-12 hours if needed. Maximum: 20 mg per treatment episode.
Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.
Terminal elimination half-life: 20-50 hours in adults; prolonged in elderly and patients with hepatic impairment (up to 100 hours).
Terminal elimination half-life: 4.5 hours (range 3–6 h); supports twice-daily dosing.
Hepatic via CYP2C19, CYP3A4, and CYP2B6; major metabolite is N-desmethyldiazepam (active); also forms oxazepam and temazepam.
Primarily metabolized via hepatic glucuronidation by UGT1A4 and UGT1A8; minor metabolism by CYP3A4; excreted mainly in feces.
Primarily renal (urinary) as glucuronide conjugates and unchanged drug; <2% excreted unchanged in feces.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
97-99% bound primarily to albumin.
98% bound to albumin and alpha-1-acid glycoprotein.
0.8-1.4 L/kg (adults); reflects extensive distribution into tissues including brain.
0.8 L/kg; indicates moderate tissue distribution.
Rectal gel: 80-100% relative to intravenous administration.
Oral: 60% (first-pass metabolism reduces to ~60% absolute).
No specific dose adjustment provided in labeling; use with caution in severe renal impairment (Cr Cl < 10 m L/min) due to propylene glycol content.
Cr Cl ≥50 m L/min: no adjustment; Cr Cl 30-49 m L/min: 400 mg every 8 hours; Cr Cl 15-29 m L/min: 300 mg every 12 hours; Cr Cl <15 m L/min or hemodialysis: 300 mg every 24 hours.
Dose reduction may be necessary in Child-Pugh Class C cirrhosis; avoid in severe hepatic impairment due to decreased clearance and propylene glycol accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: 400 mg every 8 hours; Child-Pugh C: 300 mg every 12 hours.
2 to 5 years: 0.5 mg/kg rectally; 6 to 11 years: 0.3 mg/kg; 12 years and older: 0.2 mg/kg. Dose per treatment episode not to exceed 20 mg.
For children ≥2 years: 10 mg/kg/dose IV every 8 hours, maximum 600 mg/dose.
Start at lower end of dosing range (2.5-5 mg) due to increased sensitivity and decreased clearance; monitor for excessive sedation and respiratory depression.
No specific dose adjustment based solely on age; dose based on renal function as per renal adjustment guidelines.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for patients with inadequate response to alternatives.
Increased risk of thromboembolic events including deep vein thrombosis and pulmonary embolism; increased risk of endometrial cancer, uterine sarcoma, and stroke.
Risk of respiratory depression, particularly with high doses or in elderly/chronically ill; tolerance and dependence; withdrawal symptoms; may impair cognitive and motor functions; should not be abruptly discontinued.
Risk of thromboembolic events; endometrial hyperplasia and malignancy; hepatic steatosis and elevated liver enzymes; cataracts; hypertriglyceridemia; use in pregnancy category N (should not be used during pregnancy).
Hypersensitivity to diazepam or benzodiazepines; narrow-angle glaucoma; severe respiratory insufficiency; myasthenia gravis; concomitant use with opioids (except for palliative care).
History of venous thromboembolism; pregnancy; women with a history of stroke or transient ischemic attack; hypersensitivity to azmiro or its components.
Grapefruit and grapefruit juice may increase diazepam levels and risk of toxicity; avoid concurrent consumption. Alcohol potentiates CNS depression and should be avoided. No other significant food interactions reported.
No significant food interactions. Avoid grapefruit juice as it may increase systemic budesonide exposure. Maintain adequate calcium and vitamin D intake due to potential bone density loss with long-term use.
DIASTAT ACUDIAL (diazepam) crosses the placenta. First trimester exposure is associated with a small increased risk of oral clefts (odds ratio ~1.5). In second and third trimesters, chronic use may lead to fetal benzodiazepine exposure; high doses near term can cause neonatal withdrawal (hypertonia, irritability, tremors, poor feeding) and 'floppy infant syndrome' (hypotonia, lethargy, respiratory depression). No known structural teratogenicity in later trimesters.
No human data; animal studies not conducted. Avoid in pregnancy unless benefit outweighs unknown risks. FDA Pregnancy Category N (not classified).
Diazepam is excreted into breast milk; M/P ratio is approximately 0.1-0.3. Relative infant dose estimated at 1-10% of maternal weight-adjusted dose. Neonatal accumulation possible due to long half-life (50-100 hours in preterm neonates). Breastfeeding is not recommended during chronic use due to risks of sedation, poor feeding, and withdrawal. Short-term, single-dose use may be acceptable with monitoring.
No data on excretion in human milk; unknown M/P ratio. Risk to infant cannot be excluded; consider developmental benefits of breastfeeding versus theoretical risk.
Pregnancy increases volume of distribution and decreases albumin concentration, potentially reducing diazepam peak levels. However, drug clearance is unchanged or slightly decreased. Dose adjustments are individually determined based on clinical response; no fixed rule. Lower initial doses may be considered in third trimester due to enhanced drug sensitivity. After delivery, reduce dose to pre-pregnancy levels.
No specific dose adjustments studied; pharmacokinetics in pregnancy unknown. Use lowest effective dose and monitor therapeutic response.
DIASTAT ACUDIAL is a diazepam rectal gel formulation used for acute repetitive seizures. Administer rectally; position patient on side to reduce aspiration risk. Do not administer more than 5 doses per month or more than 2 doses per single seizure episode. Monitor respiratory depression, especially with concurrent CNS depressants. Onset of action is 5-15 minutes; if seizure persists beyond 15 minutes, seek emergency medical attention. Avoid use in patients with acute narrow-angle glaucoma or severe liver disease.
AZMIRO (budesonide/albuterol) is a fixed-dose combination inhaler for asthma. Due to its LABA component, it should not be used for acute bronchospasm. Titrate to the lowest effective dose. Rinse mouth after inhalation to reduce oral candidiasis and dysphonia. Monitor for increased heart rate and blood pressure, especially with excessive use.
Use exactly as prescribed; do not exceed recommended doses.,Insert the rectal gel tip gently and hold buttocks together for 1-2 minutes after administration.,Keep a seizure diary to track episodes and medication use.,Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while using this drug.,Seek medical help if seizures worsen or if breathing difficulties occur.,Store at room temperature away from light and moisture.
Use AZMIRO exactly as prescribed, not for sudden breathing problems.,Rinse your mouth with water after each use to prevent thrush.,Do not stop taking this medication without talking to your doctor.,Tell your doctor if symptoms worsen or you need more rescue inhaler.,Avoid foods high in potassium if you are also taking diuretics.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIASTAT ACUDIAL vs AZMIRO, answered by our medical review team.
DIASTAT ACUDIAL is a Benzodiazepine Anticonvulsant that works by Binds to GABA-A receptors, enhancing GABA effects and increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of seizure activity.. AZMIRO is a Anticonvulsant that works by Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIASTAT ACUDIAL and AZMIRO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIASTAT ACUDIAL is: 2.5 mg to 20 mg rectally, as a single dose for acute seizure clusters; may repeat once after 4-12 hours if needed. Maximum: 20 mg per treatment episode.. The standard adult dose of AZMIRO is: Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIASTAT ACUDIAL and AZMIRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIASTAT ACUDIAL is classified as Category C. DIASTAT ACUDIAL (diazepam) crosses the placenta. First trimester exposure is associated with a small increased risk of oral clefts (odds ratio ~1.5). In second and third trimesters. AZMIRO is classified as Category C. No human data; animal studies not conducted. Avoid in pregnancy unless benefit outweighs unknown risks. FDA Pregnancy Category N (not classified).. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.